Peter Ruane

Peter Ruane publication distribution in Microbiology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Microbiology in 2026. The highlighted bar marks where Peter Ruane sits on this spectrum.

Peter Ruane D-index placement in Microbiology in 2026

The chart shows the D-index (discipline H-index) distribution of Microbiology scientists ranked by Research.com in 2026. The highlighted bar marks where Peter Ruane sits on this spectrum.

Best Publications

• Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection

  Jordan J. Feld;Ira M. Jacobson;Christophe Hézode;Tarik Asselah

  1332
  Citations

• Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection

  Graham R. Foster;Nezam Afdhal;Stuart K. Roberts;Norbert Bräu

  1023
  Citations

• Lopinavir–Ritonavir versus Nelfinavir for the Initial Treatment of HIV Infection

  Sharon Walmsley;Barry Bernstein;Martin King;José Arribas

  863
  Citations

• Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials

  Bonaventura Clotet;Nicholas Bellos;Jean Michel Molina;David Cooper

  666
  Citations

• Ledipasvir and Sofosbuvir for HCV in Patients Coinfected with HIV-1

  Susanna Naggie;Curtis Cooper;Michael Saag;Kimberly Workowski

  553
  Citations

• Daclatasvir plus Sofosbuvir for HCV in Patients Coinfected with HIV-1

  David L. Wyles;Peter J. Ruane;Mark S. Sulkowski;Douglas Dieterich

  525
  Citations

• Glecaprevir–Pibrentasvir for 8 or 12 Weeks in HCV Genotype 1 or 3 Infection

  Stefan Zeuzem;Graham R Foster;Stanley Wang;Armen Asatryan

  482
  Citations

• Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial.

  Kenneth H Mayer;Kenneth H Mayer;Jean-Michel Molina;Melanie A Thompson;Peter L Anderson

  430
  Citations

• Antiviral Activity, Pharmacokinetics, and Dose Response of the HIV-1 Integrase Inhibitor GS-9137 (JTK-303) in Treatment-Naive and Treatment-Experienced Patients

  Edwin Dejesus;Daniel Berger;Martin Markowitz;Calvin Cohen

  392
  Citations

• Clinical targeting of HIV capsid protein with a long-acting small molecule.

  John O. Link;Martin S. Rhee;Winston C. Tse;Jim Zheng

  386
  Citations

• Ombitasvir, Paritaprevir Co-dosed With Ritonavir, Dasabuvir, and Ribavirin for Hepatitis C in Patients Co-infected With HIV-1: A Randomized Trial

  Mark S. Sulkowski;Joseph J. Eron;David Wyles;Roger Trinh

  382
  Citations

• Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of tenofovir alafenamide as 10-day monotherapy in HIV-1-positive adults.

  Peter J. Ruane;Edwin DeJesus;Daniel Berger;Martin Markowitz

  379
  Citations

• Tenofovir DF in antiretroviral-experienced patients: results from a 48-week, randomized, double-blind study.

  Robert T Schooley;Peter Ruane;Robert A Myers;Gildon Beall

  374
  Citations

• Capsid Inhibition with Lenacapavir in Multidrug-Resistant HIV-1 Infection.

  Unknown

  330
  Citations

• Efficacy of 8 Weeks of Sofosbuvir, Velpatasvir, and Voxilaprevir in Patients With Chronic HCV Infection: 2 Phase 3 Randomized Trials

  Ira M. Jacobson;Ira M. Jacobson;Eric Lawitz;Edward J. Gane;Bernard E. Willems

  291
  Citations

• Effect of Sotrovimab on Hospitalization or Death Among High-risk Patients With Mild to Moderate COVID-19

  Unknown

  289
  Citations

• HIV-1 Protease Mutations and Protease Inhibitor Cross-Resistance

  Soo-Yon Rhee;Jonathan Taylor;W. Jeffrey Fessel;David Kaufman

  267
  Citations

• Risk Factors for Community-Associated Methicillin-Resistant Staphylococcus aureus Skin Infections among HIV-Positive Men Who Have Sex with Men

  Unknown

  247
  Citations

• Efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate given as fixed-dose combinations containing emtricitabine as backbones for treatment of HIV-1 infection in virologically suppressed adults: a randomised, double-blind, active-controlled phase 3 trial

  Joel E Gallant;Eric S Daar;François Raffi;Cynthia Brinson

  210
  Citations

• Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from dolutegravir plus abacavir and lamivudine in virologically suppressed adults with HIV-1: 48 week results of a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial.

  Jean-Michel Molina;Douglas Ward;Indira Brar;Anthony Mills

  209
  Citations